Calamos Advisors LLC Acquires 1,394 Shares of Amgen Inc. $AMGN

Calamos Advisors LLC boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 2.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 69,874 shares of the medical research company’s stock after purchasing an additional 1,394 shares during the period. Calamos Advisors LLC’s holdings in Amgen were worth $29,453,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of AMGN. State Street Corp raised its position in shares of Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after acquiring an additional 11,656,755 shares during the last quarter. Bank of America Corp DE acquired a new stake in Amgen during the 2nd quarter valued at approximately $1,831,903,000. Wellington Management Group LLP increased its position in Amgen by 1,102.7% during the 2nd quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock valued at $993,031,000 after purchasing an additional 2,514,254 shares during the period. BlackRock Inc. raised its holdings in Amgen by 4.8% during the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of Amgen by 702.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company’s stock worth $647,126,000 after purchasing an additional 1,344,010 shares during the period. 76.50% of the stock is owned by institutional investors.

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.85% of the company’s stock.

Amgen Stock Up 0.0%

AMGN stock traded up $0.14 during mid-day trading on Friday, reaching $460.42. 2,579,312 shares of the company traded hands, compared to its average volume of 2,619,150. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm’s 50 day moving average price is $422.43 and its 200 day moving average price is $378.19. The stock has a market cap of $248.92 billion, a price-to-earnings ratio of 26.71, a P/E/G ratio of 3.41 and a beta of 0.43. Amgen Inc. has a fifty-two week low of $312.39 and a fifty-two week high of $483.99.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.79 by $0.66. The company had revenue of $10.37 billion during the quarter, compared to analyst estimates of $10.07 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. Amgen’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the prior year, the company posted $5.64 earnings per share. As a group, equities research analysts predict that Amgen Inc. will post 23.33 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, November 20th. This represents a $10.08 annualized dividend and a yield of 2.2%. Amgen’s dividend payout ratio is presently 58.47%.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported quarterly earnings and revenue above expectations, with revenue up 8.5% year over year. Its earnings-call discussion also emphasized growth and pipeline momentum, supporting the case for continued expansion. Amgen Earnings Call Highlights Growth, Pipeline Momentum
• Positive Sentiment: A large real-world study found Repatha lowered heart-attack risk by 20% versus ezetimibe in patients with heart disease. The findings could strengthen the drug’s clinical and commercial position. Repatha real-world study
• Positive Sentiment: Scotiabank reiterated a Buy view and set a $530 price target; UBS also maintains a Buy rating with a $530 target. Separately, ETFs bought a net $79.8 million of AMGN shares in Wednesday’s session. Scotiabank price target ETF holdings
• Neutral Sentiment: Analyst opinions remain divided: Leerink Partners and Guggenheim have Hold/neutral ratings, while Scotiabank and UBS are more optimistic. The differing views suggest debate about how much of Amgen’s recent gains are already reflected in its valuation. Leerink Partners rating
• Negative Sentiment: Freedom Broker downgraded Amgen to Hold, adding to the cautious analyst commentary and potentially tempering enthusiasm after the recent rally. Freedom Broker downgrade

Analysts Set New Price Targets

A number of research firms have recently commented on AMGN. Citigroup upped their price objective on shares of Amgen from $405.00 to $465.00 and gave the company a “neutral” rating in a research note on Wednesday. Barclays boosted their target price on shares of Amgen from $380.00 to $400.00 and gave the company an “equal weight” rating in a report on Wednesday, October 21st. JPMorgan Chase & Co. upped their price target on shares of Amgen from $350.00 to $425.00 and gave the company a “neutral” rating in a research report on Wednesday. Bank of America increased their price target on Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a research report on Sunday, October 18th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $420.80.

About Amgen

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases.

The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally.

Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A.